Aion Therapeutic Inc.
ANTCF
$0.012
-$0.003-20.00%
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 104.60% | 44.15% | -32.20% | -45.09% | -39.47% |
| Depreciation & Amortization | 158.14% | -- | -- | -92.31% | -68.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.54% | 39.77% | -33.40% | -69.10% | -68.46% |
| Operating Income | -20.35% | -39.77% | 33.40% | 69.10% | 68.46% |
| Income Before Tax | -74.94% | -41.53% | -130.43% | 58.20% | 68.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.94% | -41.53% | -130.43% | 58.20% | 68.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.94% | -41.53% | -130.43% | 58.20% | 68.85% |
| EBIT | -20.35% | -39.77% | 33.40% | 69.10% | 68.46% |
| EBITDA | -23.63% | -- | -- | 69.02% | 68.47% |
| EPS Basic | 18.18% | -16.67% | -125.00% | 60.00% | 69.44% |
| Normalized Basic EPS | 45.45% | 0.00% | 41.67% | 68.18% | 52.17% |
| EPS Diluted | 18.18% | 12.50% | -128.21% | 57.78% | 71.79% |
| Normalized Diluted EPS | 45.45% | 0.00% | 30.00% | 68.18% | 52.17% |
| Average Basic Shares Outstanding | 114.46% | 29.21% | 17.46% | 3.90% | 3.88% |
| Average Diluted Shares Outstanding | 114.46% | 29.21% | -5.23% | 3.90% | 3.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
